
Soliton, Inc. EBITDA 2011-2026 | SOLY
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Soliton, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -14.1 M | -12.7 M | -8.08 M | -7.06 M | -7.24 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.06 M | -14.1 M | -9.84 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
753 M | $ 178.43 | 6.92 % | $ 13.4 B | ||
|
AxoGen
AXGN
|
-1.19 M | $ 33.07 | 6.7 % | $ 1.52 B | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 9.23 | 1.71 % | $ 261 M | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 12.22 | 2.3 % | $ 1.65 B | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 38.3 | 4.45 % | $ 5.71 K | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.88 | 2.73 % | $ 1.14 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 9.61 | 2.95 % | $ 740 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Inogen
INGN
|
-9.55 M | $ 6.73 | -1.03 % | $ 179 M | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.14 | 10.68 % | $ 19.3 M | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 87.26 | 2.53 % | $ 3.03 B | ||
|
Electromed
ELMD
|
10.7 M | $ 24.45 | 2.82 % | $ 207 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.95 | 1.21 % | $ 374 M | ||
|
Globus Medical
GMED
|
757 M | $ 91.99 | 2.21 % | $ 12.4 B | ||
|
LENSAR
LNSR
|
-21 M | $ 5.6 | -0.53 % | $ 67 M | ||
|
EDAP TMS S.A.
EDAP
|
-17.9 M | $ 3.36 | -1.29 % | $ 126 M | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 88.34 | 2.22 % | $ 114 B | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | ||
|
Myomo
MYO
|
-13.5 M | $ 0.68 | 0.03 % | $ 28.5 M | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.73 | 2.62 % | $ 7.57 M | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.15 | 2.47 % | $ 878 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Nevro Corp.
NVRO
|
-118 M | - | - | $ 217 M | ||
|
Stryker Corporation
SYK
|
6.46 B | $ 338.41 | 1.91 % | $ 129 B | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.62 | 1.66 % | $ 38.6 M | ||
|
Tactile Systems Technology
TCMD
|
35.9 M | $ 24.36 | 1.29 % | $ 557 M | ||
|
TransMedics Group
TMDX
|
136 M | $ 108.31 | 0.92 % | $ 3.68 B | ||
|
Tandem Diabetes Care
TNDM
|
26 M | $ 19.47 | 6.51 % | $ 1.32 B | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
898 K | $ 9.86 | 1.96 % | $ 353 M |